

CANCER RESEARCH AT SYLVESTER (FACCA ATTENDEES)

Shaun Brothers, PhD

Department: Psychiatry Research Program: Tumor Biology Email: <u>sbrothers@med.miami.edu</u>

• Discovery and development of novel therapeutics for disease, with a focus on epigenetics

Kerry L. Burnstein, PhD

Department: Molecular & Cellular Pharmacology Research Program: Tumor Biology Email: <u>kburnstein@med.miami.edu</u>

- Mechanisms of steroid hormone receptor action in endocrine cancers
- Androgen receptor signaling in prostate cancer and its role in the development of therapeutic resistance
- Molecular basis for the tumorigenic activities of Vav3/Rac1 and evaluating novel therapeutic approaches in endocrine cancers
- Mechanisms responsible for the metastasis suppressing effects of these miRs

Maria (Ken) E. Figueroa, MD

Department: Human Genetics Research Program: Cancer Epigenetics Email: <u>mef162@miami.edu</u>

- Studying the role of epigenetic modifications in transcriptional regulation during normal and malignant hemopoiesis
- Focus on how changes in normal chromatin patterns occur during malignant transformation, and how these changes may contribute to the leukemogenic process
- Using a combination of computational approaches based on genome-wide next generation sequencing data as well as in vitro and in vivo modeling

Sophia George, PhD

Department: Obstetrics & Gynecology Research Program: Cancer Control Email: <u>sophia.george@med.miami.edu</u>

• The biological determinants of breast and ovarian cancer predisposition within the population of women at highest risk for developing these aggressive diseases

Barry I. Hudson, MD

Department: Medicine Research Program: Tumor Biology Email: <u>bhudson@med.miami.edu</u>

- The role of RAGE / RAGE-ligands in cancer progression and metastasis
- How inflammation increases breast cancer metastasis
- The role of obesity and diabetes in driving breast cancer progression and metastasis

Noriyuki Kasahara, MD, PhD

Department: Cell Biology Research Program: Viral Oncology Email: <u>nkasahara@med.miami.edu</u>

- Translational development of gene therapy and oncolytic virotherapy for cancer
- Development of adoptive immunotherapy and genetically engineered cell vaccines for cancer
- Genetic engineering of hematopoietic stem cells for post-transplant chemoselection in vivo

Erin Kobetz, PhD, MPH

Department: Medicine Research Program: Cancer Control Email: <u>EKobetz@med.miami.edu</u>

- Social epidemiology
- Health inequality
- Cancer prevention and control
- Social determinants of health and health care utilization

Michelle Lin, MBA

Associate Director for Administration Department: SCCC Research Administration Email: <u>mlin@med.miami.edu</u>

- CCSG/Strategic Operations
- SCCC Recruitment and Onboarding
- SCCC Finance, Informatics, Facilities & Shared Resources
- SCCC Pre-Award & Research Activities

Stephen D. Nimer, MD

Center Director Department: Medicine Research Program: Cancer Epigenetics Email: <u>snimer@med.miami.edu</u>

- Care of patients with hematologic malignancies or bone marrow failure
- Clinical investigations of hematopoietic growth factors, and transcriptional modifying therapies
- Investigation of the molecular defects that underlie myeloid malignancies such as AML, myelodysplastic syndromes, or myeloproliferative neoplasms
- Understanding how cancer cells resist chemotherapy and radiation therapy

Eric D. Wieder, PhD

Department: Medicine Research Program: Tumor Biology Email: <u>ewieder@med.miami.edu</u>

- Flow cytometry
- Stem cell transplant
- Immune function
- Graft-versus-host disease
- Immunotherapy Roles of TET2, ASXL1 and PHF6 in the normal development of hematopoiesis

Sion L. Williams, PhD

Department: Neurology Research Program: Cancer Epigenetics Email: <u>slwilliams@med.miami.edu</u>

- The Oncogenomics Core Facility necessitates an interest in many aspects of cancer genomics. This work covers miRNAs, gene expression profiling, mutation screening and single-cell applications.
- Contribution of kilobase- to megabase-scale structural variants in cancer development
- Role of mitochondrial DNA variants in cancer development

Mingjiang Xu, MD, PhD

Department: Biochemistry & Molecular Biology Research Program: Cancer Epigenetics Email: <u>mxx51@miami.edu</u>

- Roles of TET2, ASXL1 and SETBP1 mutations in the pathogenesis of myeloid malignancies
- Roles of TETs in the pathogenesis of lymphoid malignancies
- Roles of PHF6 mutations in the pathogenesis of hematological malignancies
- Development of novel therapeutics for myeloid and lymphoid malignancies
- Roles of TET2, ASXL1 and PHF6 in the normal development of hematopoiesis